Cited by 443Dementia and Cognitive Impairment ResearchParkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Imaging amyloid deposition in Lewy body diseases

Open access
Gomperts, S. N., Rentz, D. M., Moran, E., Becker, J. A., Locascio, J. J., Klunk, W. E., Mathis, C. A., Elmaleh, D. R. +5 more·2008·Neurology

Abstract

Background: Extrapyramidal motor symptoms precede dementia in Parkinson disease (PDD) by many years, whereas dementia occurs early in dementia with Lewy bodies (DLB). Despite this clinical distinction, the neuropsychological and neuropathologic features of these conditions overlap. In addition to widespread distribution of Lewy bodies, both diseases have variable burdens of neuritic plaques and neurofibrillary tangles characteristic of Alzheimer disease (AD). Objectives: To determine whether amyloid deposition, as assessed by PET imaging with the β-amyloid–binding compound Pittsburgh Compound B (PiB), can distinguish DLB from PDD, and to assess whether regional patterns of amyloid deposition correlate with specific motor or cognitive features. Methods: Eight DLB, 7 PDD, 11 Parkinson disease (PD), 15 AD, and 37 normal control (NC) subjects underwent PiB-PET imaging and neuropsychological assessment. Amyloid burden was quantified using the PiB distribution volume ratio. Results: Cortical amyloid burden was higher in the DLB group than in the PDD group, comparable to the AD group. Amyloid deposition in the PDD group was low, comparable to the PD and NC groups. Relative to global cortical retention, occipital PiB retention was lower in the AD group than in the other groups. For the DLB, PDD, and PD groups, amyloid deposition in the parietal (lateral and precuneus)/posterior cingulate region was related to visuospatial impairment. Striatal PiB retention in the DLB and PDD groups was associated with less impaired motor function. Conclusions: Global cortical amyloid burden is high in dementia with Lewy bodies (DLB) but low in Parkinson disease dementia. These data suggest that β-amyloid may contribute selectively to the cognitive impairment of DLB and may contribute to the timing of dementia relative to the motor signs of parkinsonism. GLOSSARY: AAL = Automated Anatomic Labeling; AD = Alzheimer disease; ADRC = Alzheimer’s Disease Research Center; AMNART = American version of the National Adult Reading Test; ANCOVA = analysis of covariance; BDS = Blessed Dementia Scale; CAA = cerebral amyloid angiopathy; CDR = Clinical Dementia Rating; CDR-SB = Clinical Dementia Rating Sum of Boxes; DLB = dementia with Lewy bodies; DVR = distribution volume ratio; FCSRT = Cued Selective Reminding Test; FRSRT = Free Selective Reminding Test; H&Y = Hoehn and Yahr; MGH = Massachusetts General Hospital; MMSE = Mini-Mental State Examination; NC = normal control; NFT = neurofibrillary tangle; NPIQ = Neuropsychiatric Inventory Questionnaire; NS = not significant; PD = Parkinson disease; PDD = Parkinson disease dementia; PiB = Pittsburgh Compound B; ROI = region of interest; SPM2 = Statistical Parametric Mapping; UKPDSBRC = UK Parkinson’s Disease Society Brain Bank Research Center; UPDRS = United Parkinson’s Disease Rating Scale; WAIS-R = Wechsler Adult Intelligence Scale–Revised.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/01.wnl.0000326146.60732.d6

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The proportion of cognitively normal older adults with moderate or frequent CERAD NP score matches well with reports using fibrillar Aβ PET imaging in cognitively normal individuals.

    “The proportion of CN older adults with moderate or frequent CERAD NP score, a metric significantly correlated with Aβ peptide-immunoreactive plaque area and detergent-insoluble Aβ42 accumulation, matches well with reports using fibrillar Aβ PET imaging in cognitively normal individuals.”

    From Ecology of the Aging Human Brain (2011) · cites this paper as [35]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 43 · Cited by 443

Research works printed but not linked: 35

  1. [2]McKeith IG Dickson DW Lowe J Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium Neurology 2005 65 1863 1872 16237129
  2. [3]Lippa CF Duda JE Grossman M DLB/PDD Working Group DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers Neurology 2007 68 812 819 17353469
  3. [4]Harding AJ Halliday GM Cortical Lewy body pathology in the diagnosis of dementia Acta Neuropathol 2001 102 355 363 11603811
  4. [5]Tiraboschi P Hansen LA Alford M Cholinergic dysfunction in diseases with Lewy bodies Neurology 2000 54 407 411 10668703
  5. [6]Mattila PM Röyttä M Torikka H Dickson DW Rinne JO Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson’s disease Acta Neuropathol 1998 95 576 582 9650749
  6. [7]McKeith IG Burn D DeKosky ST Spectrum of Parkinson’s disease, Parkinson’s dementia, and Lewy body dementia Neurologic Clinics Philadelphia WB Saunders 2000 865 883 11072265
  7. [8]Aarsland D Ballard CG Halliday G Are Parkinson’s disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004 17 137 145 15312277
  8. [9]Hughes AJ Daniel SE Blankson S Lees AJ A clinicopathologic study of 100 cases of Parkinson’s disease Arch Neurol 1993 50 140 148 8431132
  9. [10]Hughes CP Berg L Danziger WL Coben LA Martin RL A new clinical scale for the staging of dementia Br J Psychiatry 1982 140 566 572 7104545
  10. [11]McKhann G Drachman DA Folstein M Katzman R Price DL Stadlan EM Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease Neurology 1984 34 939 944 6610841
  11. [13]Ferman TJ Smith GE Boeve BF DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging Neurology 2004 62 181 187 14745051
  12. [15]Grober E Buschke H Crystal H Screening for dementia by memory testing Neurology 1988 38 900 903 3368071
  13. [16]Mathis CA Wang Y Holt DP Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents J Med Chem 2003 46 2740 2754 12801237
  14. [17]Logan J Fowler JS Volkow ND Distribution volume ratios without blood sampling from graphical analysis of PET data J Cereb Blood Flow Metab 1996 16 834 840 8784228
  15. [18]Lopresti BJ Klunk WE Mathis CA Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis J Nucl Med 2005 46 1959 1972 16330558
  16. [19]Mintun MA Larossa GN Sheline YI [11C]PiB in a nondemented population: potential antecedent marker of Alzheimer disease Neurology 2006 67 446 452 16894106
  17. [20]Archer HA Edison P Brooks DJ Amyloid load and cerebral atrophy in Alzheimer’s disease: an (11)C-PiB positron emission tomography study Ann Neurol 2006 60 145 147 16802294
  18. [21]Fagan AM Mintun MA Mach RH Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans Ann Neurol 2006 59 512 519 16372280
  19. [22]Johnson KA Gregas M Becker JA Imaging of amyloid burden and distribution in cerebral amyloid angiopathy Ann Neurol 2007 62 229 234 17683091
  20. [23]Tzourio-Mazoyer N Landeau B Papathanassiou D Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain Neuroimage 2002 15 273 289 11771995
  21. [25]Rowe CC Ng S Ackermann U Imaging beta-amyloid burden in aging and dementia Neurology 2007 68 1718 1725 17502554
  22. [26]Bacskai BJ Frosch MP Freeman SH Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report Arch Neurol 2007 64 431 434 17353389
  23. [27]Maetzler W Reimold M Liepelt I [11C]PIB binding in Parkinson’s disease dementia Neuroimage 2008 39 1027 1033 18035558
  24. [28]Pike KE Savage G Villemagne VL Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease Brain 2007 130 2837 2844 17928318
  25. [29]Price JL Morris JC Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease Ann Neurol 1999 45 358 368 10072051
  26. [31]Kemppainen NM Aalto S Karrasch M Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer’s disease Ann Neurol 2008 63 112 118 18023012
  27. [32]Braak H Braak E Cognitive impairment in Parkinson’s disease: amyloid plaques, neurofibrillary tangles, and neuropil threads in the cerebral cortex J Neural Transm Park Dis Dement Sect 1990 2 45 57 2357270
  28. [33]Lockhart A Lamb JR Osredkar T PiB is a non-specific imaging marker of amyloid-beta (Aβ) peptide-related cerebral amyloidosis Brain 2007 130 2607 2615 17698496
  29. [34]Jellinger KA Prevalence of vascular lesions in dementia with Lewy bodies: a postmortem study J Neural Transm 2003 110 771 778 12811637
  30. [35]Mastaglia FL Johnsen RD Byrnes ML Kakulas BA Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson’s disease Mov Disord 2003 18 81 86 12518303
  31. [36]Klunk WE Wang Y Huang GF The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component J Neurosci 2003 23 2086 2092 12657667 PMC6741999
  32. [37]Fodero-Tavoletti MT Smith DP McLean CA In vitro characterization of Pittsburgh Compound-B binding to Lewy bodies J Neurosci 2007 27 10365 10371 17898208 PMC6673163
  33. [39]Yong SW Yoon JK An YS Lee PH A comparison of cerebral glucose metabolism in Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies Eur J Neurol 2007 14 1357 1362 17941855
  34. [40]Jellinger KA Attems J Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol 2006 112 253 260 16804711
  35. [41]Klunk WE Price JC Mathis CA Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees J Neurosci 2007 27 6174 6184 17553989 PMC3265970

Authors
Gomperts, S. N., Rentz, D. M., Moran, E., Becker, J. A., Locascio, J. J., Klunk, W. E., Mathis, C. A., Elmaleh, D. R., Shoup, T., Fischman, A. J., Hyman, B. T., Growdon, J. H., & Johnson, K. A.
Affiliations
Brigham and Women's Hospital (US)
Venue
Neurology
Published
2008-09-16
Volume
71
Issue
12
Pages
903-910
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W1982834182
Cited by
443
References
43
Citations by year
2026: 1 · 2025: 11 · 2024: 4 · 2023: 9 · 2022: 14 · 2021: 16 · 2020: 22 · 2019: 26 · 2018: 24 · 2017: 15 · 2016: 30 · 2015: 29 · 2014: 32 · 2013: 40 · 2012: 42
FWCI
29.98
Type
journal article
Language
en
Open access
Locations
  • Neurology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5p50ns038372-10, 1r21ns060310-01)
  • National Institute on Aging (R01AG018402, P01AG025204, RF1AG025516, P50AG005133, P50 AG05134, P50-AG-05133, R01AG027435, P50AG005134, R37AG025516)
  • National Institute of Neurological Disorders and Stroke (P50-NS38372, R21-NS060310)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
amyloid deposition, amyloid-beta, Pittsburgh compound B, positron emission tomography, dementia with Lewy bodies, Parkinson's disease dementia, Parkinson's disease, Alzheimer's disease, Lewy bodies, distribution volume ratio, visuospatial impairment, motor function, differential diagnosis, cognitive impairment, cerebral amyloid angiopathy
MeSH terms
Aged, Aniline Compounds, Brain, Cognition, Dementia, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Movement, Neuropsychological Tests, Parkinson Disease, Thiazoles, Tissue Distribution, Amyloid beta-Peptides, Lewy Body Disease, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review